Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
68.45-0.48 (-0.70%)
At close: 11:35 AM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close68.93
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range68.12 - 68.91
52wk Range24.83 - 93.82
1y Target EstN/A
Market Cap87.05B
P/E Ratio (ttm)21.28
Avg Vol (3m)9,830
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Reuters3 days ago

    Hard to swallow: emerging markets get tougher for drugmakers

    Emerging markets have lost their luster for Big Pharma making drug firms ever more dependent on the United States for growth just as American anger over high medicine prices is building. A few years ago, the developing world was seen as a savior as patent after patent expired across the United States and Europe, but emerging market sales growth at the top drug firms slowed to less than two percent in the latest quarter. Forecasts from independent experts IMS Health now suggest the United States will account for 55 percent of sales growth between 2016 and 2020, with emerging markets only contributing 30 percent.

  • TheStreet.com3 days ago

    New Setback for Sanofi's Lantus Increases Need for M&A

    UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

  • Reuters3 days ago

    UnitedHealth trims drug coverage, including Sanofi insulin

    In a bulletin seeking client feedback by Sept. 28, UnitedHealth said it is changing reimbursement terms for long-acting insulins and will no longer cover Lantus, the main insulin drug sold by Sanofi (SASY.PA). The insurer said Basaglar, a cheaper biosimilar insulin sold by Eli Lilly (LLY.N) would be covered as "Tier 1," meaning the lowest out-of-pocket costs for members. Levemir, produced by Novo Nordisk (NOVOb.CO), will move from Tier 1 to Tier 2.